Plasma proteomics-based biomarkers for predicting response to mesenchymal stem cell therapy in severe COVID-19.

Tian-Tian LiWei-Qi YaoHai-Bo DongZe-Rui WangZi-Ying ZhangMeng-Qi YuanLei ShiFu-Sheng Wang

Published in: Stem cell research & therapy (2023)

The responsiveness to MSC therapy appears to depend on baseline level of DDX55, AGRG6, PICAL, CTRB1, and ANXA1. Clinicians should take these factors into consideration when making decision to initiate MSC therapy in patients with severe COVID-19.

Keyphrases

coronavirus disease
sars cov
early onset
mass spectrometry
palliative care
stem cells
cell therapy
decision making